Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
42.69
-0.55 (-1.26%)
At close: Aug 22, 2025, 4:00 PM
43.00
+0.31 (0.73%)
After-hours: Aug 22, 2025, 5:23 PM EDT
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $452.05M in the quarter ending June 30, 2025, with 100.69% growth. This brings the company's revenue in the last twelve months to $944.05M, up 16.05% year-over-year. In the year 2024, Ionis Pharmaceuticals had annual revenue of $705.14M, down -10.48%.
Revenue (ttm)
$944.05M
Revenue Growth
+16.05%
P/S Ratio
7.06
Revenue / Employee
$883,115
Employees
1,069
Market Cap
6.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
| Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
| Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
| Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
| Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IONS News
- 1 day ago - US FDA approves Ionis' drug for rare genetic disorder - Reuters
- 1 day ago - DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema - Business Wire
- 23 days ago - Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug - Benzinga
- 23 days ago - Ionis reports second quarter 2025 financial results and highlights progress on key programs - Business Wire
- 4 weeks ago - TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS) - Business Wire
- 4 weeks ago - Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice - Business Wire
- 5 weeks ago - Ionis to hold second quarter 2025 financial results webcast - Business Wire